Navigation Links
Medarex and Massachusetts Biologic Laboratories Announce Primary Objective Achieved in Phase 2 Trial of Monoclonal Antibody Combination for the Treatment of Clostridium difficile Associated Diarrhea (CDAD)
Date:11/3/2008

Top-line data from randomized, double-blind, placebo controlled Phase 2 clinical trial indicate statistically significant reduction in recurrences

of CDAD

PRINCETON, N.J. and JAMAICA PLAIN, Mass., Nov. 3 /PRNewswire-FirstCall/ -- Medarex, Inc. (Nasdaq: MEDX) and The Massachusetts Biologic Laboratories (MBL) of the University of Massachusetts Medical School (UMMS) today announced that a Phase 2 trial of an anti-C. difficile antibody combination treatment in patients with C. difficile Associated Diarrhea (CDAD) successfully met its primary objective. The top-line results from the recently completed multi- center, randomized, double-blind, placebo-controlled Phase 2 trial indicated a statistically significant reduction in recurrences of CDAD when compared with placebo. In the study, 200 patients symptomatic with CDAD receiving standard of care antibiotics (metronidazole or vancomycin) were randomized to receive either intravenous placebo or intravenous administration of a combination of MDX-066 (CDA-1) and MDX-1388 (CDB-1), two fully human antibodies that neutralize C. difficile toxins A and B, respectively.

Consistent with the published literature, the recurrence rate in the placebo-treated group exceeded 20 percent for patients following successful treatment with standard of care antibiotics. In comparison with placebo, MDX- 066/MDX-1388 treatment reduced recurrence rates by approximately 70 percent (p=0.0004 on the intent-to-treat population). The antibody combination treatment was generally safe and well-tolerated. Full results from this Phase 2 trial are planned to be presented at a future scientific meeting.

The incidence and mortality associated with CDAD has been increasing(1),
'/>"/>

SOURCE Medarex, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Medarex Announces 2008 Third Quarter Financial Results
2. Medarex And PharmAthene Announce New Therapeutic Data for Anthrax Anti-Toxin, Valortim(R)
3. Medarex to Present at the UBS Global Life Sciences Conference
4. Medarex to Present at the Thomas Weisel Partners Healthcare Conference
5. BioWa and Medarex Announce License of BioWas COMPLEGENT(TM) Technology
6. Medarex Announces July 10 Live Webcast of R&D Day Event
7. Medarex to Present at the Jefferies Second Annual Healthcare Conference
8. Medarex to Present at the 29th Annual Goldman Sachs Healthcare Conference
9. Medarex to Present at the Bank of America 2008 Healthcare Conference
10. Medarex to Present at the Morgan Stanley Global Healthcare Unplugged Conference
11. Medarex Reports Phase 1/2 Clinical Data of MDX-060 in Lymphoma at American Association for Cancer Research Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... Engineering at the University of Delaware, is known ... energy engineering, environmental sustainability and electronics. , His ... with a well-defined, crystalline structure. At the atomic ... that zeolites can separate molecules with size differences ... of a nanometer), making them useful to the ...
(Date:7/24/2014)... (PRWEB) July 24, 2014 Your ... advances in modeling lithium-ion battery storage capacity. , ... from a theoretical model created at Lawrence ... that predicts how carbon components will perform ... storage emphasizes the urgent need for higher-performance batteries. ...
(Date:7/24/2014)... 2014 2014 Deep Research Report ... a professional and in-depth research report on Potassium ... basic information, including its definition, classification, application, ... research covers the international market analysis, including China’s ... covering macroeconomic environment & economic situation analysis, the ...
(Date:7/24/2014)... The first part of the session ... in Human Studies” will cover comprehensive clinical support in ... With increasing R&D costs and declining industry success in ... the knowledge collected in early Phase I/IIa study data ... late stage development. , Next, the presenters will examine ...
Breaking Biology Technology:University of Delaware researcher describes new approach for creating organic zeolites 2Getting More Life out of Lithium-ion Batteries 2Potassium Sulphate Market & SHMP Industry 2014 (Global, China) Analysis Now Available at DeepResearchReports.com 2Potassium Sulphate Market & SHMP Industry 2014 (Global, China) Analysis Now Available at DeepResearchReports.com 3Potassium Sulphate Market & SHMP Industry 2014 (Global, China) Analysis Now Available at DeepResearchReports.com 4Best Practices for Optimizing Dose Escalation in First in Human Studies, New Webinar August 6th Hosted by Xtalks 2
... April 4, 2011 Reportlinker.com announces that ... in its catalogue: Antiviral ... http://www.reportlinker.com/p0203535/Antiviral-Therapeutics---Technologies-markets-and-companies.html ... of antiviral approaches including vaccines, pharmaceuticals and ...
... 2011 Reportlinker.com announces that a new market ... Nanobiotechnologies- applications, markets and companies ... Nanotechnology is the creation and utilization of materials, ... on the nanometer-length scale (a nanometer is one ...
... 4, 2011 GeneLink, Inc. (OTCBB: GNLK, "the ... reported financial results for the fiscal year ended December 31, ... Gross margin increased from $4,906,710 in 2009 to $4,997,367 in ... 2010 as compared to $8,561,455 in 2009; Operating losses ...
Cached Biology Technology:Reportlinker Adds Antiviral Therapeutics - Technologies, Markets and Companies 2Reportlinker Adds Antiviral Therapeutics - Technologies, Markets and Companies 3Reportlinker Adds Antiviral Therapeutics - Technologies, Markets and Companies 4Reportlinker Adds Nanobiotechnologies - Applications, Markets and Companies 2Reportlinker Adds Nanobiotechnologies - Applications, Markets and Companies 3GeneLink Reports 2010 Results 2
(Date:7/25/2014)... puberty is influenced by ,imprinted genes,a subset of genes whose ... This is the first evidence that imprinted genes can control ... study were published today in the journal Nature . ... a marker for the timing of puberty in females. ... girls, is an inherited trait, and is linked to breast ...
(Date:7/24/2014)... (July 24, 2014) Scientists at The New ... one step closer to creating a viable cell ... own cells. , For the first time, ... lines from skin samples of patients with primary ... accelerated protocol to induce these stem cells into ...
(Date:7/24/2014)... species for food or commercial food sale, has been ... decline of many species of primates and other mammals. ... half of the species being consumed are birds, particularly ... only the meat made available for sale but the ... hunters and brought to villages for consumption, we noted ...
Breaking Biology News(10 mins):Could age of first period influence development of diseases in older women? 2NYSCF scientists one step closer to cell therapy for multiple sclerosis patients 2
... around the ancient spruce woodlands of eastern North ... could respond to climate change? Matt Fitzpatrick of ... Appalachian Laboratory, along with researchers from the University ... received a three-year, $670,000 award from the National ...
... Uppsala University, Sweden, instil hope of efficient hydrogen production with ... scepticism based on previous research. The study, which is published ... view on the ability of green algae which is ... producing fuel from renewable energy sources to replace the fossil ...
... Monell Center molecular neurobiologist Peihua Jiang, PhD, is ... Investigators in Gustation, an annual award presented by the ... scientist who is a rising leader in the field ... the understanding of the structure and function of taste ...
Cached Biology News:Scientists look to ancient past to better predict how species may respond climate change 2Surprising findings on hydrogen production in green algae 2Peihua Jiang receives Ajinomoto Award for Young Investigators in Gustation from AChemS 2
Goat polyclonal to Dysadherin ( Abpromise for all tested applications). entrezGeneID: 53827...
Ku80 Antibody Shipping Temperature: HOT Storage Temperature: -20C...
This antibody detects an ~25 kDa band, corresponding to the expected molecular mass of Rab3A, on immunoblots. The antibody specificity is confirmed in peptide inhibition immunoblotting studies....
Rabbit polyclonal to Shigella (HRP) ( Abpromise for all tested applications)....
Biology Products: